Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas

• DOI: 10.2147/cmar.s286322
• Publication Date: 2021-02-03T21:51:09Z
• Authors: Zhiyong Liu; Weitao Yao; Yao Zhao; Oufei Liu; Peng Zhang; Hong Ge
• Keywords: Maintenance therapy; Leukopenia; Progression-free survival

Anlotinib is a novel tyrosine kinase inhibitor with promising anti-tumor activity in patients advanced soft tissue sarcomas (STS) China. Liposomal doxorubicin monotherapy showed an encouraging effect on this disease. The aim of study was to evaluate the efficacy and safety anlotinib combined liposomal followed by maintenance metastatic STS.This multicenter, retrospective, observational study. We reviewed 27 STS from July 2018 December 2019, who were treated absence tumor progression or intolerable adverse events (AEs).Of included, 2 had complete response (CR), 9 obtained partial (PR), 11 achieved stable disease (SD). objective rate 40.7%, control 81.5%, median progression-free survival (PFS) 7 months (95% CI, 5.3-8.1 months). (PFR) at 3 6 81.5% 59.3%, respectively. Most AEs mild acceptable. most frequent grade 3/4 leukopenia (33.3%), febrile neutropenia (7.4%), anemia (7.4%). No deaths related treatment reported.This shows that effective STS, therapy are Further investigation its warranted.